Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Market Snapshot: Changes Blow In With Adderall XR Generics

Executive Summary

The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect
Advertisement

Related Content

Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market
Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market
GSK Signs On As Shire’s Vyvanse Promotion Partner
Shire’s Vyvanse Approved For ADHD
Shire Settlement With Barr Permits Generic Adderall XR Entry In 2009

Topics

Advertisement
UsernamePublicRestriction

Register

PS050869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel